Vascular endothelial cell-specific phosphotyrosine phosphatase (VE-PTP) activity is required for blood vessel development

Blood

Volumn 107, Issue 12, 2006, Pages 4754-4762

  Bäumer, Sebastian ^c   Keller, Linda ^c   Holtmann, Astrid ^c   Funke, Ruth ^c   August, Benjamin ^c   Gamp, Alexander ^c   Wolburg, Hartwig ^c   Wolburg Buchholz, Karen ^c   Deutsch, Urban ^b   Vestweber, Dietmar ^a  

^a MAX PLANCK INSTITUTE FOR MOLECULAR BIOMEDICINE   (Germany)

^b UNIVERSITY OF BERN   (Switzerland)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

FIBRONECTIN; PROTEIN TYROSINE PHOSPHATASE; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTERY ENDOTHELIUM; ARTICLE; CELL MEMBRANE; CELL PROLIFERATION; CONGENITAL BLOOD VESSEL MALFORMATION; EMBRYO DEVELOPMENT; ENDOTHELIUM CELL; ENZYME ACTIVITY; MOUSE; NONHUMAN; PREGNANCY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION;

EID: 33745107561     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-01-0141     Document Type: Article

References (38)

1. Risau W. Mechanisms of angiogenesis. Nature. 1997;386:671-674.
2. Gale NW, Yancopoulos GD. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev. 1999;13:1055-1066.
3. Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003;9:653-660.
4. Jain RK. Molecular regulation of vessel maturation. Nat Med. 2003;9:685-693.
5. Ferrara N, Gerber H-P, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669-676.
6. Carmeliet P, Lampugnani M-G, Moons L, et al. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell. 1999;98:147-157.
7. Gory-Faure S, Prandini MH, Pointu H, et al. Role of vascular endothelial-cadherin in vascular morphogenesis. Development. 1999;126:2093-2102.
8. Crosby CV, Fleming PA, Argraves WS, et al. VE-cadherin is not required for the formation of nascent blood vessels but acts to prevent their disassembly. Blood. 2005;105:2771-2776.
9. den Hertog J, Blanchetot C, Buist A, Overvoorde J, van der Sar A, Tertoolen LG. Receptor protein-tyrosine phosphatase signalling in development. Int J Dev Biol. 1999;43:723-733.
10. Koop EA, Gebbink MF, Sweeney TE, et al. Impaired flow-induced dilation in mesenteric resistance arteries from receptor protein tyrosine phosphatase-mu-deficient mice. Am J Physiol Heart Circ Physiol. 2005;288:H1218-H1223.
11. Takahashi T, Takahashi K, St John PL, et al. A mutant receptor tyrosine phosphatase, CD148, causes defects in vascular development. Mol Cell Biol. 2003;23:1817-1831.
12. Fachinger G, Deutsch U, Risau W. Functional interaction of vascular endothelial-protein-tyrosine phosphatase with the angiopoietin receptor Tie-2. Oncogene. 1999;18:5948-5953.
13. Krueger NX, Streuli M, Saito H. Structural diversity and evolution of human receptor-like protein tyrosine phosphatases. EMBO J. 1990;9:3241-3252.
14. Nawroth R, Poell G, Ranft A, et al. VE-PTP and VE-cadherin ectodomains interact to facilitate regulation of phosphorylation and cell contacts. EMBO J. 2002;21:4885-4895.
15. Shalaby F, Rossant J, Yamaguchi TP, et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature. 1995;376:62-66.
16. Dumont DJ, Gradwohl G, Fong GH, et al. Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev. 1994;8:1897-1909.
17. Reiss Y, Kiefer F. Immortalization of endothelial cells. In: Augustin HG, ed. Methods in Endothelial Cell Biology. Berlin: Springer; 2004:63-72.
18. Gotsch U, Borges E, Bosse R, et al. VE-cadherin antibody accelerates neutrophil recruiment in vivo. J Cell Sci. 1997;110:583-588.
19. Koblizek TI, Runting AS, Stacker SA, Wilks AF, Risau W, Deutsch U. Tie2 receptor expression and phosphorylation in cultured cells and mouse tissues. Eur J Biochem. 1997;244:774-779.
20. Kataoka H, Takakura N, Nishikawa S, et al. Expressions of PDGF receptor alpha, c-Kit and Flk1 genes clustering in mouse chromosome 5 define distinct subsets of nascent mesodermal cells. Dev Growth Differ. 1997;39:729-740.
21. Morgan SM, Samulowitz U, Darley L, Simmons DL, Vestweber D. Biochemical characterization and molecular cloning of a novel endothelial specific sialomucin. Blood. 1999;93:165-175.
22. Bosse R, Vestweber D. Only simultaneous blocking of L- and P-selectin completely inhibits neutrophil migration into mouse petritoneum. Eur J Immunol. 1994;24:3019-3024.
23. Hahne M, Jäger U, Isenmann S, Hallmann R, Vestweber D. Five TNF-inducible cell adhesion mechanisms on the surface of mouse endothelioma cells mediate the binding of leukocytes. J Cell Biol. 1993;121:655-664.
24. Dorner AA, Wegmann F, Butz S, et al. Coxsackievirus-adenovirus receptor (CAR) is essential for early embryonic cardiac development. J Cell Sci. 2005;118:3509-3521.
25. Drake CJ, Fleming PA. Vasculogenesis in the day 6.5 to 9.5 mouse embryo. Blood. 2000;95:1671-1679.
26. Djonov V, Baum O, Burri PH. Vascular remodeling by intussusceptive angiogenesis. Cell Tissue Res. 2003;314:107-117.
27. Drake CJ, Little CD. Exogenous vascular endothelial growth factor induces malformed and hyperfused vessels during embryonic neovascularization. Proc Natl Acad Sci U S A. 1995;92:7657-7661.
28. Sato TN, Tozawa Y, Deutsch U, et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature. 1995;376:70-74.
29. Sui XF, Kiser TD, Hyun SW, et al. Receptor protein tyrosine phosphatase microregulates the paracellular pathway in human lung microvascular endothelia. Am J Pathol. 2005;166:1247-1258.
30. Koop EA, Lopes SM, Feiken E, et al. Receptor protein tyrosine phosphatase mu expression as a marker for endothelial cell heterogeneity: analysis of RPTPmu gene expression using LacZ knock-in mice. Int J Dev Biol. 2003;47:345-354.
31. Keane MM, Lowrey GA, Ettenberg SA, Dayton MA, Lipkowitz S. The protein tyrosine phosphatase DEP-1 is induced during differentiation and inhibits growth of breast cancer cells. Cancer Res. 1996;56:4236-4243.
32. Trapasso F, Iuliano R, Boccia A, et al. Rat protein tyrosine phosphatase eta suppresses the neoplastic phenotype of retrovirally transformed thyroid cells through the stabilization of p27(Kip1). Mol Cell Biol. 2000;20:9236-9246.
33. Lampugnani MG, Zanetti A, Corada M, et al. Contact inhibition of VEGF-induced proliferation requires vascular endothelial cadherin, beta-catenin, and the phosphatase DEP-1/CD148. J Cell Biol. 2003;161:793-804.
34. Radice GL, Rayburn H, Matsunami H, Knudsen KA, Takeichi M, Hynes RO. Developmental defects in mouse embryos lacking N-cadherin. Dev Biol. 1997;181:64-78.
35. Yang JT, Rayburn H, Hynes RO. Embryonic mesodermal defects in α5 integrin-deficient mice. Development. 1993;119:1093-1105.
36. Majno G, Palade GE, Schoefl GI. Studies on inflammation, II: the site of action of histamine and serotonin along the vascular tree: a topographic study. J Biophys Biochem Cytol. 1961;11:607-626.
37. Horan KL, Adamski SW, Ayele W, Langone JJ, Grega GJ. Evidence that prolonged histamine suffusions produce transient increases in vascular permeability subsequent to the formation of venular macromolecular leakage sites: proof of the Majno-Palade hypothesis. Am J Pathol. 1986;123:570-576.
38. Copp AJ. Death before birth: clues from gene knockouts and mutations. Trends Genet. 1995;11:87-93.